ASP 8302

Drug Profile

ASP 8302

Alternative Names: ASP8302

Latest Information Update: 31 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astellas Pharma
  • Class Urologics
  • Mechanism of Action Muscarinic M3 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bladder dysfunction

Most Recent Events

  • 30 Apr 2018 Astellas Pharma completes a phase I trial for Bladder dysfunction (In volunteers) in Japan (NCT03361540)
  • 07 Feb 2018 Phase-II clinical trials in Bladder dysfunction in Europe and Japan (PO) (Astellas Pharma pipeline, February 2018)
  • 14 Nov 2017 Astellas Pharma initiates enrolment in a phase I trial for Bladder dysfunction (In volunteers) in Japan(NCT03361540)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top